# Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2

> **NCT03916094** · PHASE1 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 11 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HLX22

## Key facts

- **NCT ID:** NCT03916094
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-31
- **Primary completion:** 2021-01-04
- **Final completion:** 2021-12-27
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03916094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03916094, "Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03916094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*